Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can magnetic pulses curb cannabis cravings? small trial aims to find out

NCT ID NCT06114212

Symptom relief Sponsor: St. Joseph's Healthcare Hamilton Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether deep transcranial magnetic stimulation (dTMS) targeting specific brain regions is safe and tolerable for people with moderate-to-severe cannabis use disorder. Twelve adults who used cannabis at least four days per week received the stimulation. The main goals were to see if the procedure was feasible and acceptable, while also measuring any changes in cannabis use and cravings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep repetitive transcranial magnetic stimulation (dTMS) via H4 coil
What this could lead to
If this approach proves feasible and safe, it could pave the way for a larger study testing whether dTMS can help reduce cannabis use and cravings.
What could go wrong
This is a very early, small pilot study with only 12 participants and no placebo group. It is designed to test feasibility, not effectiveness, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Mar 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult, age 25-65 * DSM-5 CUD, moderate or higher (4+ DSM-5 symptoms) * 4 or more days of cannabis use per week * Reports inhalation as one route of administration * Treatment-seeking (i.e., self-reported readiness to change of 5 or greater on a 0-10 readiness ruler) * Stable domicile and reliable transportation, and willingness to attend in-person visits at SJHH Hamilton. Exclusion Criteria: * Current psychotic symptoms, history of schizophrenia-spectrum disorders or bipolar disorder, or current PTSD * Active suicidality (past 3 months) or history of severe suicidality (i.e., requiring hospitalization) * Any other mental health condition deemed incompatible by the team * High risk alcohol involvement and/or 4+ symptoms of alcohol use disorder * Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months * Current unstable medical condition (e.g., diabetes) * rTMS Contraindications: intracranial or metal implants in the head or nearby regions that cannot be safely removed; history of epilepsy or seizures; pregnancy (female participants only); pacemaker and/or implantable cardioverter-defibrillators). * Medication contraindications (e.g., bupropion \>300 mg/day due to risk of seizures, benzodiazepine equivalent dose to lorazepam \>2 mg/day). * History of recurrent headache or migraine (past year) * Significant literacy, visual, or hearing problems * Co-enrollment in a clinical drug trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder

Contacts and locations

Locations

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 3K7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.